Drug Profile

VT 301

Alternative Names: VT-301; VT301 - VT Bio

Latest Information Update: 16 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator VT BIO
Class Antidementias; Regulatory T lymphocyte cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Alzheimer's disease

Most Recent Events

16 Jan 2024 VT 301 is still in phase I trial in Alzheimer's disease in South Korea (Parenteral) (VT Bio pipeline, January 2024)
28 Dec 2023 No recent reports of development identified for phase-I development in Alzheimer's-disease(In the elderly, In adults) in South Korea (Parenteral, Injection)
01 Nov 2020 Phase-I clinical trials in Alzheimer's disease (In adults, In the elderly) in South Korea (Parenteral) (NCT05016427)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com